283 withdrawn. 283 Phase 2, 85 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 283 | Withdrawn 283 |
| Phase 1 | 85 | Withdrawn 85 |
| Phase 3 | 4 | Withdrawn 4 |
Follow Lymphoproliferative Disorders: new trials by email Literature Review of Lymphoproliferative Disorders trials Research Report on Lymphoproliferative Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma Belantamab mafodotin - Relapsed/Refractory Multiple Myeloma | Phase 2 | Withdrawn | Cristiana Costa Chase, DO | 2026-11-01 | 2026-09-28 | |
| Pre-emptive Anakinra for Cytokine Event Reduction Anakinra (Kineret®) - B-Acute Lymphoblastic Leukemia, CAR-T Cell Therapy | Phase 1 / Phase 2 | Withdrawn | Kevin McNerney | 2026-10-01 | 2026-08-13 | |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-07-01 | 2026-06-09 | |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| Clinical Study on CAR-T Targeting Igβ Targets in Refractory Relapsed Non-Hodgkin's Lymphoma Chimeric Antigen Receptor T Cells (CAR-T) Targeting Igβ Targets - Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | Phase 2 | Withdrawn | The First Affiliated Hospital of Soochow University | 2026-05-26 | 2026-06-03 | |
| Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides A-dmDT390-bisFv(UCHT1), Vorinostat - Mycosis Fungoides | Phase 2 | Withdrawn | Virogen Biotechnology Inc. | 2026-05-01 | 2026-05-18 | |
| Investigation of the Efficacy of Metformin Therapy on Pulmonary Sarcoidosis Metformin, Cellulose - Sarcoidosis, Pulmonary | Phase 2 | Withdrawn | University of Maryland, Baltimore | 2025-12-10 | 2025-02-11 | |
| Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy Daratumumab Injection - ALL, Adult | Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-12-01 | 2026-05-13 | |
| A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Tazverik (Tazemetostat) - Follicular Lymphoma, Refractory Follicular Lymphoma | Phase 2 | Withdrawn | Epizyme, Inc. | 2025-09-02 | 2026-01-30 | |
| Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma HY004 - Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-09-01 | 2025-08-08 | |
| A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma Epcoritamab, Lenalidomide, Tafasitamab - Lymphoma | Phase 2 | Withdrawn | Memorial Sloan Kettering Cancer Center | 2025-08-13 | 2026-04-07 | |
| Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy GOLCADOMIDE, Nivolumab - Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | University of Pittsburgh | 2025-06-30 | 2026-04-13 | |
| A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Pirtobrutinib, Acalabrutinib - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Withdrawn | AstraZeneca | 2025-06-30 | 2025-06-05 | |
| A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL) HY004, Cyclophosphamide, Fludarabine Phosphate - B-cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Withdrawn | Juventas Cell Therapy Ltd. | 2025-06-30 | 2025-08-08 | |
| A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma Glofitamab - B-cell Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2025-06-06 | 2025-09-17 | |
| Clinical Trial of CD38 Monoclonal Antibody Combined With Chemotherapy for T-Cell Acute Lymphoblastic Leukemia Pediatric-Inspired Chemotherapy Regimen - T-ALL | Phase 1 / Phase 2 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2025-04-30 | 2026-05-14 | |
| Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy Interferon Beta-1A, X-Ray Imaging, Echocardiography - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Withdrawn | Fred Hutchinson Cancer Center | 2025-04-01 | 2024-07-12 | |
| Tyrosine Kinase 2 (TYK2) for GA and CS Deucravacitinib - Sarcoidosis, Granuloma Annulare | Phase 2 | Withdrawn | Yale University | 2025-03-01 | 2025-04-29 | |
| Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells Commercial CAR-T, Investigational CAR-T - Malignancy, Cancer | Phase 1 / Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2025-01-20 | 2026-01-06 | |
| Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM Siltuximab, Teclistamab(FDA-approved) - Multiple Myeloma, Cytokine Release Syndrome | Phase 2 | Withdrawn | Jack Khouri, MD | 2025-01-01 | 2025-03-03 |
Showing 20 of 283. Sign in to see all of them.
Multiple Myeloma (85) · Lymphoma (61) · Leukemia, Lymphocytic, Chronic, B-Cell (48) · Lymphoma, Large B-Cell, Diffuse (36) · Lymphoma, Non-Hodgkin (35) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (34) · Burkitt Lymphoma (31) · Lymphoma, Follicular (31) · Recurrence (30) · Leukemia (28) · Lymphoma, Mantle-Cell (23) · Lymphoma, B-Cell (19) · Hodgkin Disease (18) · Leukemia, Myeloid, Acute (18) · Lymphoma, B-Cell, Marginal Zone (18)
Hemic and Lymphatic Diseases (281) · Immune System Diseases (281) · Immunoproliferative Disorders (277) · Neoplasms by Histologic Type (276) · Neoplasms (270) · Lymphatic Diseases (207) · Hematologic Diseases (168) · Pathological Conditions, Signs and Symptoms (97) · Hemorrhagic Disorders (96) · Paraproteinemias (96) · Pathologic Processes (96) · Lymphoma (95) · Blood Protein Disorders (94) · Cardiovascular Diseases (94)
Dexamethasone (46) · Rituximab (36) · Cyclophosphamide (32) · Lenalidomide (26) · Bortezomib (23) · Calcium Dobesilate (19) · Melphalan (17) · Etoposide (16) · Bendamustine Hydrochloride (13) · Doxorubicin (11) · Methotrexate (11) · Vincristine (11) · daratumumab (11) · fludarabine phosphate (11) · Cytarabine (10)
M.D. Anderson Cancer Center (22) · National Cancer Institute (NCI) (14) · University of Arkansas (7) · Fred Hutchinson Cancer Center (5) · Masonic Cancer Center, University of Minnesota (5) · City of Hope Medical Center (4) · Hoag Memorial Hospital Presbyterian (4) · Mayo Clinic (4) · UNC Lineberger Comprehensive Cancer Center (4) · University of Michigan Rogel Cancer Center (4) · Celgene (3) · GlaxoSmithKline (3) · Institute of Hematology & Blood Diseases Hospital, China (3) · Karyopharm Therapeutics Inc (3) · Memorial Sloan Kettering Cancer Center (3)
United States (132) · China (11) · Canada (10) · France (9) · Germany (9) · Italy (7) · Spain (7) · United Kingdom (7) · Australia (4) · Belgium (3) · Israel (3) · Netherlands (3) · Switzerland (3) · Denmark (2) · South Korea (2)
Robert O. Dillman, MD, FACP (4) · Carl O Landgren, M.D. (3) · Yago Nieto, MD, PHD (3) · Claudio Brunstein, MD, PhD (2) · Faith Davies, MD (2) · Li Li, MD (2) · Michael Choi, MD (2) · Stanislaw R. Burzynski, MD, PhD (2) · Adam J Olszewski, MD (1)
PMID 34515338, PMID 24443277, PMID 18003886, PMID 18390837, PMID 20408846, PMID 22045986, PMID 23815981, PMID 23927993, PMID 25795722, PMID 28148715, PMID 31433920, PMID 32632956
2017 (4), P30CA015083 (4), P30CA015704 (4), P30CA016672 (4), P30CA072720 (3), U10CA032102 (3), U10CA180820 (3), 2015 (2), P30CA043703 (2), 2014 (1), 2018 (1), 2023 (1), 2025 (1), K12TR005104 (1), P01CA018029 (1)